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Development of acquired resistance to tamoxifen is a major clinical problem during endocrine treatment in estrogen receptor positive breast
cancer. Transforming growth factor-β1 (TGF-β) has been implicated in tamoxifen-induced cellular signaling in breast cancer, and increased Akt
activation is associated with tamoxifen-resistant cell types. We hypothesized that the relationship between TGF-β and Akt signaling may be
involved in the development and progression of tamoxifen resistance. Tamoxifen-resistant (Tam-R) cells were established from parental MCF-7
cells by continuously exposing them to 4-hydroxytamoxifen (4-OHT). Tam-R cells were associated with a decrease in TGF-β1 secretion, TGF-β-
mediated transcriptional response, and growth inhibitory effects of 4-OHT. Tam-R cells expressed significantly higher levels of phosphorylated
Akt and lower levels of phosphorylated Smad 3 in both the absence and presence of 4-OHT when compared to MCF-7 cells treated with 4-OHT.
Ectopic expression of constitutively active Akt (Myc-AktMyr) rendered MCF-7 cells resistant to activation by TGF-β and the growth inhibitory
effects of 4-OHT, while over-expression of kinase-dead Akt (Myc-AktK179M) or LY294002 treatment of Tam-R cells enhanced TGF-β activation
and blocked cell growth. These results suggest that suppression of TGF-β signaling by activated Akt is correlated with the development of
tamoxifen resistance in breast cancer.
© 2007 Elsevier B.V. All rights reserved.Keywords: Tamoxifen; Akt; Transforming growth factor-β; Breast cancer1. Introduction
The anti-estrogen tamoxifen, or its active metabolite 4-
hydroxytamoxifen (4-OHT), is a selective estrogen receptor
(ER) modulator that can be used as a first-line treatment for ER-
positive metastatic breast cancer [1,2]. Although a majority of
patients initially benefit from treatment with tamoxifen, 50%
of all metastatic breast cancer patients who receive tamoxifen
therapy eventually acquire tamoxifen resistance [3]. A number
of studies have aimed to elucidate the mechanisms of tamoxi-
fen resistance in ER-positive breast cancers [4–7]. Recent evi-
dence suggests that there is a relationship between the ER and
growth factor receptor pathways [4–8]. For example, there may
be a relationship between the epidermal growth factor receptor
(EGFR/HER2) family and the insulin-like growth factor recep-
tor (IGFR) family [4–7]. More recently, evidence has sug-⁎ Corresponding author. Tel.: +82 2 818 6778; fax: +82 2 862 4453.
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doi:10.1016/j.bbamcr.2007.12.001gested that the action of tamoxifen in breast cancer is mediated
in part by regulation of transforming growth factor-β (TGF-β)
isoforms in tumor tissue [8–10]. Studies examining the effects of
tamoxifen on TGF-β expression have demonstrated that ta-
moxifen leads to release of active TGF-β1 from latent precursor
molecules and increased transcription of TGF-β2 and TGF-β
receptor type II (TβRII) [11–13]. Colletta et al. report that ta-
moxifen increases the secretion of negative regulators, such as
TGF-β1, in human fetal stromal cell lines. These negative regu-
lators then act in a post-translational manner without increasing
TGF-β mRNA production by tamoxifen [14]. Anti-estrogens
induce the secretion of TGF-β1 via a nontranscriptional pathway,
whereas TGF-β1 itself induces TGF-β2 by a direct transcrip-
tional mechanism [11]. In addition, anti-estrogens selectively in-
duce TβRII but not TβRI mRNA expression [12].
TGF-β is a pleiotropic cytokine with potent anti-mitogenic
and pro-apoptotic effects in many cancer cells [15–17]. Cel-
lular response to TGF-β signals is regulated in part by speci-
fic downstream intracellular effectors called Smad proteins
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tors (TβRІ and TβRII) with intrinsic serine/threonine kinase
activity [20,21]. The constitutively active kinase domain of
TβRII subsequently activates TβRІ by transphosphorylation
of serine and threonine residues in the GS box of its cyto-
plasmic domain [22]. Phosphorylation at these residues fur-
ther propagates the signaling cascade by binding to receptor-
regulated Smads (R-Smads; i.e., Smad 2 and Smad 3) [23–26].
Receptor-associated R-Smads heterodimerize with common
mediator Smad (Co-Smads; Smad 4) [27] and then relay sig-
nals from the cell membrane to the nucleus, where they bind to
Smad binding element (SBE) sequences in the promoter re-
gions of various target genes that regulate cell growth [28–30].
Inhibitory Smads (I-Smads), including Smad 6 and Smad 7,
bind to TβRІ and suppress activation of R-Smads. After li-
gand stimulation, I-Smads translocate from the nucleus to the
cytoplasm, where they associate with TβRІ and inhibit the
phosphorylation of R-Smads, resulting in inhibition of TGF-β
family signaling [29,30].
Loss of sensitivity to the TGF-β/Smad-induced cell growth
inhibition and apoptosis pathway is believed to be a major factor
in tumor formation and progression [31,32]. Reduced levels of
TGF-β signaling are also frequently observed in various cancers
[33]. In addition, recent studies suggest that several non-Smad
signaling entities, including themitogen-activated protein kinases
ERK, JNK, and p38 [33–35], the phosphatidylinositol 3-kinase
(PI3-K) [36], and Ras- and Rho-GTPases [37], mediate the
cellular effects of TGF-β. Moreover, both high levels of Akt and
high Ras activity block the TGF-β anti-proliferative response
[36,37]. Interestingly, although TGF-β can induce Akt and Ras
in a Smad-independent manner in certain cellular contexts, the
induction of Akt activity can selectively block TGF-β-induced
apoptosis [38,39].
Protein kinase B/Akt, which is composed of three closely
related isoforms (Akt1, Akt2, and Akt3), plays a crucial role as a
mediator of growth factor signaling, cell proliferation, cell sur-
vival, and apoptotic inhibition [40,41]. Akt is activated fol-
lowing the agonist-induced stimulation of PI3-K, which consists
of p85 catalytic and p110 regulatory subunits. Akt then phos-
phorylates multiple proteins implicated in cell cycle control to
ultimately stimulate cell growth [42]. Akt plays a role in cell
proliferation by phosphorylating and inactivating the kinase
GSK-3β, which prevents the GSK-3β-mediated nuclear exclu-
sion and proteolysis of cyclin D [43].
Recently, it has been reported that enhanced growth factor
signaling involving members of the EGF family [6,44] and
increased levels of PI3-K and Akt [45,46] via various signal
transduction pathways may lead to anti-estrogen resistance.
Perry et al. have demonstrated that tamoxifen acts on breast
cancer cells to stimulate TGF-β1 secretion [13]. These findings
raise the intriguing possibility that the TGF-β signaling path-
way and activity of Akt may be altered in tamoxifen-resistant
cells. Therefore, we examined whether signal transduction via
TGF-β and Akt is required for the growth of tamoxifen-resistant
cells. We found that the activation of Akt enhanced tamoxifen-
resistant (Tam-R) cell proliferation by blocking TGF-β signaling
downstream of Smad 3 activation.2. Materials and methods
2.1. Cell culture and cell growth assays
The human breast carcinoma cell line MCF-7 was obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and maintained ac-
cording to instructions provided by the ATCC. For estrogen-free cell culture,
MCF-7 cells were cultured in media containing phenol-red free RPMI-1640
supplemented with 10% charcoal stripped fetal bovine serum (FBS). The
tamoxifen-resistant (Tam-R) cell line was established from parental MCF-7 cells
by 2 months of continuous exposure to 10−6 M 4-hydroxytamoxifen (4-OHT,
Sigma-Aldrich, Dorset, UK) until a cell line resistant to the growth inhibitory
properties of 4-OHT developed. After this period, Tam-R cells were grown in
phenol-red free RPMI-1640 supplemented with 10% charcoal stripped FBS in
the absence of 4-OHT (10−6 M) for 2 months.
For cell growth assays, cells were plated at a density of 2×104 cells per well in
six-well plates and grown in phenol-red free medium supplemented with 10%
charcoal stripped FBS either in the absence or presence of 10−6M4-OHTor control
vehicle (EtOH). Cells were then trypsinized and counted at the indicated times.
2.2. Reagents
Recombinant human TGF-β1 and anti-TGF-β neutralizing antibody were
purchased from R & D Systems. LY294002 was purchased from Calbiochem
(SanDiego, CA). Phospho-Akt (Ser473), anti-Akt, phospho-GSKα/β (Ser29/9),
phospho-Smad 3 (Ser433/435), phospho-Smad 2, anti-Smad 4, anti-Smad 7, and
anti-Myc antibodies were obtained from Cell Signaling Technology (Beverly,
MO), while anti-β-actin antibodies were bought from Sigma, and Myc-AktMyr,
Myc-AktK179M, and Myc were purchased from Upstate Biotechnology (Lake
Placid, NY).
2.3. Transient transfection
All procedures were performed as indicated in the figure legends. MCF-7
and Tam-R cells were plated at a density of 1×105 cells per well in six-well
plates and transfected with 1 μg Myc, 1 μg Myc-AktMyr, or 1 μg Myc-AktK179M
using Lipofectamine 2000 (Invitrogen).
2.4. Western blot analysis
Cells were transfected with plasmids, as indicated in the figure legends, and
lysed with RIPA buffer (50 mMTris, 150 mMNaCl, 1% Triton X-100, 0.1% SDS,
and 1% NaDeoxycholate [pH 7.4]) supplemented with protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 10 μg/ml peptasin A, 10 μg/ml aprotinin, and 5 μg/
ml leupeptin). Protein concentrations were measured using Bio-rad protein assay
kits (BioRad, Hercules, CA). Protein lysates were resolved by SDS-PAGE, and
then transferred onto nitrocellulose membranes (Hybond™-P, Amersham Bio-
sciences, Piscataway, NJ), blocked with PBS containing 0.2% Tween 20 and 5%
nonfat dry milk, and then incubated first with primary antibody, and then horse-
radish peroxidase-labeled secondary antibody. Signalswere detected onX-ray film.
2.5. Luciferase assay
Cells were plated at a density of 3×104 cells per well in six-well plates and
co-transfected with a reporter plasmid (0.5 μg) (pTARE-Luc cis reporter or pCIS-
CK negative control) and pRL-TK vector (an internal control for standardization,
0.1 μg), Myc-AktMyr (0.5 μg), or Myc-AktK179M (0.5 μg) using Lipofectamine
2000 and then treated with 4-OHT (10−6 M) or TGF-β1 (10 ng/ml) for 24 h. For
experiments using LY294002, 24 h after transfection cells were treated with
either vehicle or LY294002 for 6 h before harvesting. Luciferase activity was
measured using luciferase assay kits (Promega) and normalized with β-Gal
activity.
2.6. TGF-β1 quantitation
Cells were plated at a density of 5×104 cells per well in six-well plates,
cultured under serum-free conditions, and then treated with or without 10−6 M
Fig. 1. Effect of 4-OHT on the proliferation of MCF-7 and Tam-R cells.
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medium to avoid carryover of latent TGF-β1 in serum. Following exposure to
4-OHT (10−6 M) for 24 or 72 h, amounts of TGF-β1 released into cell culture
supernatants were measured using Quantikine human TGF-β1 Immunoassay kits
(R&D Systems,Milwaukee,WI). Briefly, acid-activated samples and standards in
triplicate were added to the precoated microplates and incubated at room tem-
perature for 2 h. A second antibody, anti-TGF-β1 polyclonal antibody, was then
added to complete the sandwich followed by TGF-β1-horseradish peroxidase
conjugate. TGF-β1was detected by adding the chromogenic substrate, followed by
stop solution. Absorbance was determined at OD 450 nm.
2.7. TGF-β neutralization
TGF-β neutralization studies were performed using a neutralizing anti-
TGF-β antibody (R & D Systems). TGF-β antibody completely neutralizes the
activities of the isomeric forms TGF-β1, TGF-β2, and TGF-β3. Cells were in-
cubated with medium containing anti-TGF-β antibody (20 μg/ml) or a control
normal IgG antibody.
2.8. Anchorage-independent growth assays
Cells were cultured in phenol-red free RPMI supplemented with 10% charcoal
stripped FBS, and soft agar assays were done in six-well plates. After 14 days,
colonies were fixed and stained with nitroblue tetrazolium, and then colony num-
bers were counted.
2.9. Statistical analysis
Statistical comparisons were performed using two-tailed Student's t tests. Data
are given as mean±SEM. Significance was defined as ⁎Pb0.05, ⁎⁎Pb0.01, and
⁎⁎⁎Pb0.001.(A) MCF-7 (•) and Tam-R (▫) cells were seeded on six-well plates in steroid-
free medium, and cell growth was determined every two days by trypan blue
exclusion. The results for the above graphs are expressed as standard deviation
from three independent experiments conducted in triplicate. P value was cal-
culated compared with MCF-7 culture; * Pb0.05. (B) MCF-7 and Tam-R cells
were treated with 4-OHT (10−6 M) or control vehicle (Con) for 5 days, and cell
growth was determined. Cell growth in the presence of 4-OHT is expressed as a
percentage of a control vehicle at 5 days of growth. These data represent
standard deviation from three independent experiments conducted in triplicate.
P value was calculated compared with MCF-7 culture treated with 4-OHT;
⁎⁎Pb0.01.3. Results
3.1. TGF-β signaling in MCF-7 and Tam-R cells
Although tamoxifen, or 4-OHT, is an important endocrine
agent for the treatment of ER-positive breast cancer patients,
initially responsive tumors eventually develop resistance [1,3].
To elucidate the molecular mechanism responsible for this re-
sistance, we developed cell lines with acquired tamoxifen re-
sistance (Tam-R) from 4-OHT-sensitive parentalMCF-7 cells by
continuously exposing them to 4-OHT for 2 months. After this
period, the subsequent growth of Tam-R cells was maintained
in the absence of 4-OHT for 2 months. We first determined
whether Tam-R cells developed resistance to the anti-estrogenic
action of 4-OHT. Cell growth inhibition assays of MCF-7 and
Tam-R cells cultured in steroid-free medium showed elevated
basal growth of Tam-R cells in the absence of exogenously
added 4-OHT (Fig. 1A). Additional treatment with 4-OHT for
24 h of MCF-7 and Tam-R cells produced different results;
MCF-7 cells exhibited a significant (51.4%) decrease in cell
growth, whereas almost no decrease was observed in Tam-R
cells (Fig. 1B).
TGF-β is an autocrine regulator of cell growth in MCF-7
cells, and tamoxifen acts on breast cancer cells to stimulate its
secretion [8,12,13]. To investigate if the altered TGF-β signaling
pathway for tamoxifen is associated with the development of
resistance, we examined the secretion of TGF-β1 protein using
specific ELISAs to quantitate TGF-β1 in the media of parental
and resistant Tam-RMCF-7 cell cultures. TGF-β1 secretion wasmeasured 24 and 72 h after both cell types were treated with
either 4-OHT or control vehicle. Prior to TGF-β1 assays, the
samples assayed were acid-activated, and thus the TGF-β1 mea-
sured represented total quantities secreted by these cells. Treat-
ment of MCF-7 cells with 4-OHTcaused a significant increase in
TGF-β1 secretion, which reached levels 2.5-fold above those in
cultures treated with the control vehicle after 72 h (Fig. 2A).
Conversely, in Tam-R cells, there was no significant difference
in the levels of secreted TGF-β1 between cells treated with either
4-OHT or control vehicle.
We next studied the effects of 4-OHT on TGF-β regulated
transcriptional activity using the pTARE-Luc cis reporter plas-
mid, which contains the basic promoter element (TATA box) and
TGF-β response element (TARE), or a pCIS-CK negative con-
trol. This reporter plasmid expresses firefly luciferase under
control of these elements, whereas the pCIS-CK negative control
plasmid contains no inducible cis-enhancer element, allowing us
to evaluate whether effects are TGF-β signaling-specific. After
24 h, transcript levels of TGF-β-inducible genes in MCF-7 cells
treated with 4-OHT, as measured by pTARE-Luc cis reporter
Fig. 2. TGF-β signaling in MCF-7 and Tam-R cells. (A) MCF-7 and Tam-R cells were plated in six-well plates, cultured under serum-free conditions, and then treated
with 4-OHT (10−6 M) or control vehicle for 24 or 72 h. Following exposure to 4-OHT or control vehicle for the indicated times, the assayed samples were acid-
activated, and levels of secreted TGF-β1 were measured as described in Materials and methods. Bars represent standard deviation from three independent experiments
conducted in triplicate. n.s., not significant. (B) MCF-7 and Tam-R cells co-transfected with 0.5 μg pTARE-Luc plasmid, 0.5 μg pCIS-CK, and 0.1 μg pRL-TK vector
were treated with 4-OHT (10−6 M) or control vehicle. After 24 h, luciferase activities were then measured and normalized to Renilla luciferase activity. Data represents
the standard deviation from five independent experiments conducted in triplicate. P value was calculated compared with MCF-7 culture treated with control vehicle;
⁎⁎Pb0.01, n.s., not significant. (C) MCF-7 cells were treated with 4-OHT (10−6 M), control vehicle, or a combination of either neutralizing anti-TGF-β antibody
(TGF-β Ab, 20 μg/ml) or control IgG antibody with 4-OHT (10−6 M) in complete medium for 5 days, and cell growth was determined by trypan blue exclusion. Cell
growth is expressed as a percentage of the control vehicle at 5 days of growth. The results represent the standard deviation from five independent experiments
conducted in triplicate. P value was calculated compared with MCF-7 culture treated with 4-OHT; ⁎⁎Pb0.01. (D) Tam-R cells were incubated in growth medium
supplemented with the indicated concentrations of TGF-β1, and cell growth was evaluated at day five by trypan blue exclusion and expressed as a percentage of the
untreated control. Bars represent standard deviation from three independent experiments conducted in triplicate. P value was calculated in comparison to non-treated
Tam-R cells; ⁎⁎Pb0.01.
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treated with control vehicle (Fig. 2B). However, promoter acti-
vity was only slight greater in Tam-R cells treated with 4-OHT
compared to cells treated with control vehicle (PN0.05).
Given the reduction of TGF-β1 secretion and transcript levels
of TGF-β-inducible genes in Tam-R cells, we wanted to deter-
mine whether TGF-β activity is required for 4-OHT-induced
growth inhibition of MCF-7 cells or the proliferation of Tam-R
cells. To examine the potential role of TGF-β activity in 4-OHT-
induced growth inhibition of MCF-7 cells, we measured MCF-7
cell growth 5 days after treating cultures with 4-OHT or control
vehicle in the absence or presence of either neutralizing anti-
TGF-β antibody or control IgG antibody. As shown in Fig. 2C,
growth of MCF-7 cells was significantly inhibited by treat-
ment with 4-OHT, whereas combined treatment with 4-OHTand
neutralizing anti-TGF-β antibody completely reversed the in-hibitory effect. Treatment of these cells with control IgG anti-
body had no effect on growth, in either the absence or presence
of 4-OHT. The remarkable reversal of the inhibitory effect of
neutralizing anti-TGF-β antibody on 4-OHT in MCF-7 cells
suggests that TGF-β activity is required for the suppression of
growth by 4-OHT inMCF-7 cells. Likewise, taking into account
that treatment with exogenous TGF-β can induce growth inhi-
bition of Tam-R cells, we compared the growth of exogenous
TGF-β1-treated and non-treated Tam-R cells. Importantly, the
addition of exogenous TGF-β1 for 24 h resulted in pronounced
suppression of the growth of Tam-R cells in comparison to non-
treated Tam-R cells (Fig. 2D), indicating that the loss of TGF-β
activity might be involved in the tamoxifen resistance of MCF-7
cells.
To elucidate the molecular mechanism by which 4-OHT-
stimulated TGF-β response was blocked in Tam-R cells, we next
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by TGF-β was affected by 4-OHT. As Smads are the best char-
acterized mediators of TGF-β signaling, we first assayed the
expression of Smad proteins in cell extracts prepared fromMCF-7
and Tam-R cells treated with 4-OHTor control vehicle. As shown
in Fig. 3A, after 24 h, 4-OHT-sensitive MCF-7 cells treated with
4-OHT displayed a significant increase in the phosphorylation of
Smad 3 in comparison to cells treated with control vehicle. On the
other hand, Tam-R cells exhibit low amounts of phosphorylated
Smad 3, even in the absence of exogenously added 4-OHT, com-
pared with MCF-7 cells treated with 4-OHT. Moreover, addi-
tional treatment with 4-OHT did not have a significant effect on
phospho-Smad 3 expression levels in Tam-R cells as compared to
MCF-7 cells. Meanwhile, 4-OHT had little effect on the expres-
sion levels of Smad 4 (Co-Smads), Smad 6, or Smad 7 (I-Smad)
in both MCF-7 and Tam-R cells. In MCF-7 cells, blockade of
TGF-β signaling by exposure to neutralizing anti-TGF-β anti-
body for 24 h also completely reversed the induction of phospho-
Smad 3 expression by stimulation of 4-OHT, but we did not seen
any major changes in phospho-Smad 3 protein levels in com-
bination with control IgG antibody as compared to MCF-7 cells
treated with 4-OHT alone (Fig. 3B). Furthermore, as shown in
Fig. 2D, Tam-R cells produced a significant increase in activated
Smad 3 protein levels 24 h after addition of exogenous TGF-β,
comparedwith untreated controls (Fig. 3C). In all cases, there was
no change observed in the expression of Smad 3. These results
collectively indicate that TGF-β–Smad 3 activation may be cor-
related with the Tam-R phenotype.Fig. 3. 4-OHT regulation of Smad 3 activity in MCF-7 and Tam-R cells. (A) MCF-7
vehicle for 24 h. Western blotting with Smad 3, p-Smad 3, Smad 4, and Smad 7 antibo
vehicle, or a combination of either neutralizing anti-TGF-β antibody (20 μg/ml) or c
expression levels of phosphorylated Smad 3 were then determined by Western blott
indicated concentrations of TGF-β1. After 24 h, Western blotting with Smad 3 and p3.2. Akt activation has an important role in the suppression of
TGF-β response in Tam-R cells
Song et al. report that insulin growth factor-І (IGF-І) func-
tions via a PI3K/Akt pathway to block several TGF-β-mediated
responses, including gene transcription, apoptosis, and Smad 3
activation [47,48]. The authors suggest that Akt blocks Smad 3
activation by sequestering it from TGF-β receptors. Recently,
other groups have also reported that Akt phosphorylation is
significantly higher in tamoxifen-resistant cells grown under
basal conditions [45,46]. Because it has been reported that sig-
naling via Akt is required for anti-estrogen-resistant cell growth
and that Akt blocks TGF-β signals downstream of Smad 3
activation, we next explored whether the kinase activity of Akt
is involved in the suppression of TGF-β signals in Tam-R cells.
Using Western blotting, we first compared levels of total Akt
expression and activated Akt in MCF-7 cells and Tam-R cells
treated with 4-OHT or control vehicle for 24 h. We found that
while the phosphorylation of Ser473 in Akt was reduced in
MCF-7 cells treated with 4-OHT, it was strongly induced in
Tam-R cells in both the absence and presence of 4-OHT when
compared to MCF-7 cells treated with 4-OHT (Fig. 4A). No
significant reduction could be observed following treatment of
Tam-R cells with 4-OHT as compared to control vehicle. Ex-
pression of total Akt was not altered in either cell type, and the
same held true for total Smad 3 expression.
To further ascertain that this increase in phosphorylatedAktwas
associated with 4-OHT-induced TGF-β activity, we performedcells were incubated in growth medium containing 4-OHT (10−6 M) or control
dies was carried out. (B) MCF-7 cells were treated with 4-OHT (10−6 M), control
ontrol IgG antibody with 4-OHT (10−6 M) in complete medium for 5 days. The
ing. (C) Tam-R cells were incubated in growth medium supplemented with the
-Smad 3 antibodies was carried out. In all cases, β-actin was used as a control.
Fig. 4. Effect of Akt activity on TGF-β signaling suppression in MCF-7 and Tam-R cells. (A) MCF-7 cells were incubated in growth medium containing 4-OHT
(10−6 M) or control vehicle for 24 h, andWestern blotting with Smad 3, p-Smad 3, Akt, and p-Akt antibodies was carried out. (B)MCF-7 cells were treated with 4-OHT
(10−6 M), control vehicle, or a combination of either neutralizing anti-TGF-β antibody (20 μg/ml) or control IgG antibody with 4-OHT (10−6 M) in complete medium
for 5 days. The expression levels of phosphorylated Akt and phosphorylated Smad 3were determined. (C)MCF-7 cells were co-transfected with 0.5 μg ofMyc (Vector)
or 0.5 μg ofMyc-AktMyr and 0.5 μg of pTARE-Luc cis reporter plasmid or 0.1 μg of pRL-TK vector. Twenty-four hours after transfection, cells were treated with 4-OHT
or control vehicle. After incubating for 24 h, pTARE-Luc and Smad 3 activities were measured by luciferase assay. The amount of luciferase activity was normalized
to Renilla luciferase activity. Data represent the standard deviation from three independent experiments conducted in triplicate. P value was calculated compared
with vector transfectants treated with 4-OHT; ⁎Pb0.05. (D) Tam-R cells were co-transfected with 0.5 μg of Myc (Vector) or 0.5 μg of Myc-AktK179M and 0.5 μg of
pTARE-Luc cis reporter plasmid or 0.1 μg of pRL-TK vector. Twenty-four hours after transfection, cells were changed to medium supplemented with 10−6 M 4-OHT
or vehicle for 24 h before measuring luciferase activity. Tam-R cells were also treated with either LY294002 (10 μM) or vehicle for 2 h. The amount of luciferase
activity was measured and normalized to Renilla luciferase activity. Data represent the standard deviation from three independent experiments conducted in triplicate.
P values were calculated compared with vector transfectants treated with 4-OHT; ⁎⁎Pb0.01. (E) For (C) experiments, Western blotting with Smad 3, p-Smad 3, Myc-
Akt, and phospho-GSK-3α/β (Ser21/9) antibodies was carried out. (F) For (D) experiments, Western blotting with Smad 3, p-Smad 3,Myc-Akt, and phospho-GSK-3α/
β (Ser21/9) antibodies was carried out. In all cases, β-actin was used as a control. Expression of these Akt mutants and their kinase activity were confirmed byWestern
blotting for Myc and phospho-GSK-3α/β (Ser21/9), respectively.
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treated with 4-OHTor control vehicle in the presence or absence of
either neutralizing anti-TGF-β antibody or control IgG antibody.After 24 h, 4-OHT induced higher expression levels of
phosphorylated Smad 3 but decreased the levels of phosphorylated
Akt compared to control vehicle. As expected, combined treatment
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lower levels of phosphorylated Smad 3 and higher levels of
phosphorylated Akt at 24 h compared with single treatment with
4-OHT. Namely, blockade of TGF-β1 signaling by neutralizing
anti-TGF-β antibody completely reversed Smad 3 activation by
4-OHT, but significantly enhance Akt phosphorylation (Fig. 4B).
However, a combination of control IgG antibody did not give rise
to detectable alteration in the expression levels of phosphorylated
Smad 3 or phosphorylated Akt as compared with single treat-
ment with 4-OHT. Taken together, these findings suggest that
the increased kinase activity of Akt in Tam-R cells may lead to
persistent 4-OHT-stimulated TGF-β response and, consequently,
to the maintenance of the tamoxifen-resistant phenotype.
We next wanted to determine whether the kinase activity of Akt
is important for the suppression of TGF-β signaling inTam-R cells.
Accordingly, we compared the abilities of constitutively active
myristoylated (Myr; N-terminal fusion with Src aa 1–11, Myc-
AktMyr) and kinase-dead (KD) (K179M mutant, Myc-AktK179M)
Akt constructs to control the transcriptional responses of TGF-β by
4-OHT in both cell types treated with 4-OHTor control vehicle. In
order to determine if over-expression of activatedAkt can block the
4-OHT-inducedTGF-β response,MCF-7 cellswere co-transfected
with Myc-AktMyr or control vector along with the pTARE-Luc
cis reporter construct. Twenty-four hours after transfection, either
4-OHT or control vehicle was added before measurement of
luciferase levels. MCF-7 vector transfectant exhibited a higher
luciferase activity in response to 4-OHT than control vehicle.
In contrast, Myc-AktMyr-over-expression in MCF-7 cells de-
creased the ability of 4-OHT to stimulate TARE-dependent
transactivation compared with vector transfectant (Fig. 4C). To
determine if Akt hyperactivation in Tam-R cells results in
suppression of 4-OHT-induced luciferase activity, Tam-R cells
were co-transfected with Myc-AktK179M, which functions as a
dominant negative (DN) of Akt kinase, and pTARE-Luc cisFig. 5. Effect of Akt activity on TGF-β-regulated proliferation of Tam-R cells.
(A) Tam-R cells were transfected with 1 μg of Myc (Vector) or 1 μg of Myc-
AktK179M. Twenty-four hours after transfection, cells were treated with 4-OHT
(10−6 M), control vehicle or LY294002 (10 μM) and cultured in soft agar con-
tainingG418. After growth under the respective treatment conditions for 14 days,
cells were stained with nitroblue tetrazolium before cell colonies were counted.
Cell growth is expressed as a percentage of vector transfectants treated with
control vehicle at 14 days of growth. Data represent the standard deviation from
three independent experiments conducted in triplicate. P values were calculated
compared with vector transfectants treated with 4-OHT; ⁎Pb0.05, ⁎⁎⁎Pb0.001.
(B) MCF-7 cells transfected with 1 μg of Myc (Vector) or 1 μg of Myc-AktMyr
were treated with 4-OHT (10−6 M) or control vehicle and cultured in soft agar
containing G418. The mean colony number was measured after growth under the
respective treatment conditions for 14 days. Cell growth is expressed as a
percentage of vector transfectants treated with control vehicle at 14 days of
growth. Data represent the standard deviation from three independent experi-
ments conducted in triplicate. P values were calculated compared with vector
transfectants treated with 4-OHT; ⁎⁎Pb0.01. (C) The anchorage-independent
colony-forming assay with the above Tam-R transfected cell (A) was performed
in the presence of TGF-β1 (10 ng/ml), 4-OHT (10−6M), or 4-OHT plus TGF-β1.
Cell growth is expressed as a percentage of untreated control at 14 days of
growth. Data represent the standard deviation from three independent experi-
ments conducted in triplicate. ⁎⁎Pb0.01 (Myc-AktK179M transfectants compared
with vector transfectants in the presence of TGF-β1), ⁎⁎†Pb0.01 (Myc-
AktK179M transfectants compared with vector transfectants in the presence of
both TGF-β1 and 4-OHT).
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hicle. Twenty-four hours after transfection, the basal activation
of luciferase, even in the absence of 4-OHT, was enhanced two-
fold in Tam-R cells transfected with Myc-AktK179M compared
with the vector in the absence or presence of 4-OHT (Fig. 4D).
Notably, luciferase levels in Myc-AktK179M transfectants were
raised four-fold in response to 4-OHTas comparedwith the vector
transfectants treated with 4-OHT. Similar to the increased ex-
pression of Myc-AktK179M in TAM-R cells, the PI3K inhibitor
LY294002 reversed the suppression of TGF-β-induced luciferase
activity in the absence of 4-OHT as compared with vector trans-
fectants treated with 4-OHT. Furthermore, additional treatment
with 4-OHT in the presence of LY294002 significantly increased
luciferase activity three-fold compared to vector transfectants
treated with 4-OHT. Together, these results support the concept
that Akt activation in Tam-R cells plays an important role in the
activation of TGF-β-induced luciferase by 4-OHT.
We next questioned if the ability of Akt to suppress TGF-β
signaling is associated with the inhibition of Smad 3 activation.
To test this, MCF-7 cells transfected with control vector or Myc-
AktMyr were treated with 4-OHTor control vehicle. After 24 h of
treatment, Western blot analysis was then performed using anti-
phospho-Smad 3 antibody. As shown in Fig. 4E, the ectopic
expression of Myc-AktMyr suppressed Smad 3 phosphorylation
in the presence of 4-OHT versus MCF-7 cells transfected with
control vector. The expression levels of Myc-Akt and phospho-
GSK-3α/β (Ser21/9) were expected for each treatment. More-
over, additional 4-OHT treatment of Tam-R cells transfected
with Myc-AktK179M caused a strong enhancement in the expres-
sion levels of phosphorylated Smad 3 compared with control
transfectants. Meanwhile, inhibition of Akt activity, even in the
absence of 4-OHT, exerted a small increase in phosphorylated
Smad 3 expression in Tam-R cells compared to the vector trans-
fectants treated with either control vehicle or 4-OHT (Fig. 4F).
Inhibition of Akt activity by incubation with LY294002 for 2 h
exerted a greater increase in phosphorylated Smad 3 levels than
that brought about by transfection with Myc-AktK179M in the
Tam-R cells in the absence of 4-OHT. The expression levels of
Myc-Akt and phospho-GSK-3α/β (Ser21/9) were expected for
each treatment. Collectively, these data strongly support the no-
tion that Smad 3 activation is involved in Akt signal transduction
in Tam-R cells.
To study the effect of Akt on the 4-OHT-induced growth
inhibition of Tam-R cells, Tam-R cells transfected with control
vector or Myc-AktK179M were treated with 4-OHT or control
vehicle. Anchorage-independent soft agar assays were then per-
formed on these cells at 14 days of growth (Fig. 5A). Transfection
with Myc-AktK179M suppressed the basal growth of Tam-R cells
by 28.2% compared with control vector. Treatment of Myc-
AktK179M transfectant cells with 4-OHT resulted in further inhi-
bition of colony growth to 58% of vector transfectant cells treated
with 4-OHT. Consistent with TGF-β-induced luciferase activity,
treatment of vector transfectants with LY294002 led to a decrease
in colony formation, and combined treatment with LY294002
and 4-OHT resulted in significant colony growth suppression to
70.1% of vector transfectant cells treated with 4-OHT. In addi-
tion, colony growth showed a marked reduction of responsive-ness to 4-OHT in MCF-7 cells transfected with Myc-AktMyr as
compared with the vector transfectants (Fig. 5B). Overall, these
results provide strong support that inactivation of Akt affects
Tam-R cell proliferation.
To further explore the relationship between Akt-TGF-β
signaling and response to growth inhibitory actions of 4-OHT,
Tam-R cells transfected with Myc-AktK179M or control vector
were treated with 4-OHT, TGF-β1, or 4-OHT plus TGF-β1 be-
fore measuring the proliferation of these cells using anchorage-
independent soft agar assays. Cell growth was then monitored at
14 days of growth. TGF-β1 treatment of vector transfectants
reduced the number of colonies by approximately 25% both in
the absence and presence of 4-OHTcompared with the untreated
control (Fig. 5C). In addition, levels of growth inhibition were
59% and 79% higher in Myc-AktK179M transfectant treated with
TGF-β1 alone and co-treated with 4-OHT, respectively, than the
vector transfectants. These data suggest that inactivation of Akt
signaling is associated with TGF-β-induced cellular response
and, in the presence of 4-OHT, is important for the resistant
phenotype associated with TGF-β.
4. Discussion
Although the anti-estrogen tamoxifen is still extensively used
as an adjuvant endocrine therapy for women with early-stage
ER-positive breast cancer and a first-line treatment in metastatic
breast cancer, the mechanism of tamoxifen resistance acquisi-
tion has not been verified until recently [1,2]. The mechanism
whereby tamoxifen resistance develops in breast cancer cells
that are initially sensitive to tamoxifen treatment remains poorly
understood. Here, we provide evidence that the suppression of
TGF-β signaling via Akt activation may be involved in the de-
velopment of tamoxifen resistance in breast cancer cells.
Recent reports have shown that TGF-β1 secretion is stimu-
lated by tamoxifen and that increased TGF-β signaling by
tamoxifen correlates with growth inhibition [8–10]. Therefore,
we studied the possibility that alterations in TGF-β1 signaling
act in a direct manner to stimulate Tam-R cell proliferation using
breast cancer cells unresponsive to tamoxifen (4-OHT) (a model
system developed by our laboratories). Perry et al. showed that
long-term incubation of MCF-7 cells with tamoxifen induces
TGF-β mRNA and protein expression. They also demonstrated
that these effects are associated with the effects of tamoxifen on
blockade at G1/G0 and the induction of apoptosis [13]. Inter-
estingly, our results also revealed that 4-OHT treatment induced
both TGF-β1 production and MCF-7 cell growth inhibition,
whereas Tam-R cells showed reduced TGF-β1 production and
resisted TGF-β-mediated cell growth inhibition (Fig. 2). To
support the involvement of TGF-β signaling in tamoxifen resis-
tance, we initially assayed luciferase activity using a pTARE-
Luc cis, TGF-β-response reporter construct. Luciferase activity
was largely enhanced by 4-OHT in MCF-7, but not Tam-R, cells
(Fig. 2B). In addition, the neutralization of active TGF-β by
neutralizing anti-TGF-β antibody reversed the growth inhibitory
effect of 4-OHT on MCF-7 cells, and treatment of Tam-R cells
with exogenous TGF-β1 led to pronounced suppression of the
growth of Tam-R cells (Fig. 2C, D). Smad 3 phosphorylation
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Tam-R cells (Fig. 3A). Taken together, these results indicate that
the loss of the TGF-β anti-proliferative response is implicated in
the mechanism of resistance to tamoxifen.
Tamoxifen's action in breast cancer is believed to bemediated
in part by the regulation of TGF-β isoforms in tumor tissues [13].
However, the molecular mechanism that leads to impairment of
the tumor-suppressive function of TGF-β in tamoxifen-resistant
cells remains to be clarified. Recent studies report that TGF-β
can cooperate with HER-2 to promote metastasis in different
models, and it has been suggested that TGF-β can act directly on
epithelial cells expressing HER-2 to induce invasive behavior
[49,50]. One possible explanation is that tamoxifen bound to the
ER induces the release of active TGF-β from its latent precursor
molecule, and that this enhances the expression of HER-2, which
ultimately diminishes the anti-proliferative action of TGF-β.
Another explanation is that up-regulation of Akt mediated by
TGF-β or TGF-β-induced RASmay block TGF-β expression or
signal transduction. However, further investigation is necessary
to elucidate the mechanisms involved.
TGF-β receptors, which function as tumor suppressors in
normal and preneoplastic tissues, acquire oncogenic functions
during tumor progression [29]. TGF-β receptors are mutated or
expressed at substantially attenuated levels in a variety of human
cancers, and these are correlated with the acquisition of resis-
tance to growth suppression by TGF-β [19,20]. These relations
suggest that a reduced expression of TGF-β receptors is re-
sponsible for altered tamoxifen sensitivity. Thus, we performed
Western blot assays using anti-TβRІ and TβRII antibodies, but
found that neither MCF-7 nor Tam-R cells showed altered TβRІ
or TβRII expression after 4-OHT treatment (data not shown).
These data demonstrate that a loss of TGF-β signaling in Tam-R
cells is blocked via the autocrine/paracrine release of TGF-β1 or
TGF-β downstream of Smad 3 activation.
Several groups have found that Akt blocks the ability of TGF-β
to activate Smad 3, mediates TGF-β-induced gene expression,
and induces apoptosis [38,39]. The potential importance of
the relationship between the Akt cell survival pathway and ta-
moxifen resistance has also been demonstrated by other labo-
ratory studies. Clarke et al. showed that adding LY294002 to
tamoxifen significantly increased the pro-apoptotic effects of
tamoxifen in a cell line that showed high levels of Akt activity [2].
Moreover, a significant increase in the level of phospho-Akt
and in the inhibition of cell growth by LY294002 was reported
in anti-estrogen resistant cells by Frogne and Jordan [45,46]. In
the present study, we tested the possibility that enhanced levels of
phospho-Akt in Tam-R cells partially block TGF-β-mediated
growth inhibition by suppressing the activation of Smad 3. As
shown in Figs. 4 and 5, inhibition of PI3-K/Akt activity either
by transfection with Myc-AktK179M or treatment with LY294002
in Tam-R cells suppressed TGF-β signaling. Moreover, our
data show that the enforced activation of Akt by transfection of
MCF-7 cells with Myc-AktMyr suppressed TGF-β response by
4-OHT. Our data thus suggest that enhanced activation of Akt
results in a loss of TGF-β response induced by tamoxifen and
that this is followed by the enhanced proliferation of Tam-R
cells.The mechanism that causes increased Akt activation in
tamoxifen-resistant cells is under intense investigation by nu-
merous groups [45,46]. One possible mechanism of increased
Akt activation in tamoxifen-resistant cells involves an altered
Akt activation mechanism, such as a mutation leading to the
absence of the PTEN protein [51,52]. However, it has been
reported that PTEN is detectable in breast carcinoma cells that
exhibit Akt activation [45]. Alternatively, the studies of Jordan
et al. demonstrate that the ligands of epidermal growth factor
receptor (EGFR), including EGF and TGFα (transforming
growth factor α), show an increased ability to activate Akt in
tamoxifen-resistant cells [46]. More studies need to be carried
out to elucidate these mechanisms.
Although our data suggest that TGF-β/pSmad 3 suppression
by Akt is involved in the mechanism of tamoxifen resistance, the
mechanism by which Akt blocks Smad 3 activation by TGF-β
remains unclear. Physical interactions between Akt and Smads
3, 4, and 7 may be required for the blockade of the phospho-
activation of Smad 3 by Akt.
Overall, our data strongly support a new mechanism for ac-
quired resistance to tamoxifen, inwhich the suppression of TGF-β
signal transduction via Akt activity is essential for the develop-
ment of breast cancer resistance to tamoxifen. We believe that a
better understanding of the function of Akt in TGF-β signaling is
likely to impact therapy in tamoxifen-resistant patients.
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